NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on developing treatments for nervous system damage, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Mr. Mike Kelly, President & CEO of NervGen, will deliver a presentation on Tuesday, September 10, 2024, at 9:30 a.m. EDT. The company's management team will also be available for one-on-one meetings with investors throughout the conference, providing an opportunity for in-depth discussions about NervGen's innovative approaches to treating nervous system damage.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotech in fase clinica focalizzata sullo sviluppo di trattamenti per danni al sistema nervoso, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento è programmato per il 9-11 settembre 2024, presso il Lotte New York Palace Hotel a New York City.
Il sig. Mike Kelly, Presidente e CEO di NervGen, presenterà il suo intervento martedì 10 settembre 2024, alle 9:30 EDT. Il team di gestione dell'azienda sarà anche disponibile per incontri individuali con gli investitori durante la conferenza, offrendo un'opportunità per discussioni approfondite sulle innovative strategie di NervGen nel trattamento dei danni al sistema nervoso.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica enfocada en desarrollar tratamientos para daños en el sistema nervioso, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para el 9-11 de septiembre de 2024, en el Lotte New York Palace Hotel en la ciudad de Nueva York.
El Sr. Mike Kelly, Presidente y CEO de NervGen, realizará una presentación el martes 10 de septiembre de 2024, a las 9:30 a.m. EDT. El equipo de gestión de la empresa también estará disponible para reuniones individuales con los inversores durante la conferencia, brindando una oportunidad para discusiones detalladas sobre los enfoques innovadores de NervGen para tratar los daños en el sistema nervioso.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)는 신경계 손상 치료제를 개발하는 임상 단계의 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕 시의 Lotte New York Palace Hotel에서 개최됩니다.
NervGen의 사장 겸 CEO인 마이크 켈리는 2024년 9월 10일 화요일 오전 9시 30분 EDT에 발표를 진행할 예정입니다. 회사의 경영진 팀은 컨퍼런스 기간 동안 투자자들과의 일대일 미팅을 통해 신경계 손상 치료를 위한 NervGen의 혁신적인 접근 방식에 대한 심도 있는 논의를 진행할 기회를 제공합니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements pour les lésions du système nerveux, a annoncé sa participation à la 26e Conférence Annuelle Globale d'Investissement H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024, à l'Hôtel Lotte New York Palace à New York.
M. Mike Kelly, Président et CEO de NervGen, fera une présentation le mardi 10 septembre 2024, à 9h30 EDT. L'équipe de direction de l'entreprise sera également disponible pour des réunions individuelles avec les investisseurs tout au long de la conférence, offrant l'occasion d'échanger en profondeur sur les approches innovantes de NervGen pour la traitement des lésions du système nerveux.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien bei Nervenschäden konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York City statt.
Herr Mike Kelly, Präsident und CEO von NervGen, wird am Dienstag, den 10. September 2024, um 9:30 Uhr EDT eine Präsentation halten. Das Management-Team des Unternehmens wird während der gesamten Konferenz auch für Einzelgespräche mit Investoren zur Verfügung stehen und die Möglichkeit bieten, eingehende Diskussionen über die innovativen Ansätze von NervGen zur Behandlung von Nervenschäden zu führen.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at 9:30 a.m. EDT. Members of management will be available for one-on-one investor meetings during the conference.
The conference is being held in-person September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, NY.
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen's lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company's initial target indication, spinal cord injury. The company has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291-R, a rodent analog of NVG-291, has been shown to promote nervous system repair and functional recovery in animal models of spinal cord injury (acute and chronic intervention), peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination. NVG-291 has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration.
Contacts
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646.942.5604
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the subject matter to be presented at the upcoming investor conference; the objectives, timing and study design of the clinical development of NVG-291 in spinal cord injury; the development plans and prospective target indications for NVG-300; and the creation of innovative treatments of nervous system damage due to trauma or disease.
Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company's ability to manage the effects of pandemics such as COVID-19; the accuracy of the Company's financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of pandemics such as COVID-19, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's Annual Information Form, Prospectus Supplement, financial statements and Management Discussion and Analysis which can be found on SEDARplus.ca. All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221157
FAQ
When is NervGen Pharma (NGENF) presenting at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
Who will be presenting for NervGen Pharma (NGENF) at the investment conference?
Will NervGen Pharma (NGENF) management be available for meetings during the conference?
What is the focus of NervGen Pharma's (NGENF) research and development?
